Verdoia M, Rolla R, Negro F, et al. - Researchers investigated how platelet reactivity in patients taking Ticagrelor can be influenced by homocysteine levels. They performed platelet function evaluation at 30-90 days after discharge in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary revascularization and receiving dual antiplatelet therapy with ASA + Ticagrelor (90mg/twice a day). Using Multiple Electrode Aggregometry, they performed aggregation tests. Findings although revealed elevated platelet reactivity related to hyperhomocysteinemia in patients with ACS but such phenomenon could be overcome by using DAPT with ticagrelor, and an adequate platelet inhibition was achieved in most of the patients.